| 产品名称： | GL1 |
|---|---|
| 商品货号： | TS212116 |
| Organism： | Rattus norvegicus (B cell); Mus musculus (myeloma), rat (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody reacts with the B7-2 (GL1) antigen present on activated mouse B cells. B7-2 shows minimal expression on unstimulated B cells, but is expressed at high density on activated B cells. |
| Derivation： | Spleen cells were fused with Sp2/0-Ag14 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against mouse B7-2 antigen |
| Cellular Products： | immunoglobulin; monoclonal antibody; against mouse B7-2 antigen |
| Comments： | Animals were immunized with LPS activated DBA/2J mouse B cells. Spleen cells were fused with Sp2/0-Ag14 myeloma cells. The antibody reacts with the B7-2 (GL1) antigen present on activated mouse B cells. The B7-2 antigen is a ligand for CTLA-4 (T cell activation molecule). B7-2 shows minimal expression on unstimulated B cells, but is expressed at high density on activated B cells. It is distinct from B7-1 (previously referred to as B7). |
| Complete Growth Medium： | RPMI 1640 medium with 1% nonessential amino acids and 0.05 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Isotype： | IgG2a |
| Name of Depositor： | G Lazlo, KS Hathcock |
| Deposited As： | rat (B cell); mouse (myeloma) |
| References： | Hathcock KS, et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262: 905-907, 1993. PubMed: 7694361 Freeman GJ, et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7- deficient mice. Science 262: 907-909, 1993. PubMed: 7694362 Hancock WW, et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA 93: 13967-13972, 1996. PubMed: 8943044 Freeman GJ, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262: 909-911, 1993. PubMed: 7694363 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | GL1 |
|---|---|
| 商品货号： | TS212116 |
| Organism： | Rattus norvegicus (B cell); Mus musculus (myeloma), rat (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody reacts with the B7-2 (GL1) antigen present on activated mouse B cells. B7-2 shows minimal expression on unstimulated B cells, but is expressed at high density on activated B cells. |
| Derivation： | Spleen cells were fused with Sp2/0-Ag14 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against mouse B7-2 antigen |
| Cellular Products： | immunoglobulin; monoclonal antibody; against mouse B7-2 antigen |
| Comments： | Animals were immunized with LPS activated DBA/2J mouse B cells. Spleen cells were fused with Sp2/0-Ag14 myeloma cells. The antibody reacts with the B7-2 (GL1) antigen present on activated mouse B cells. The B7-2 antigen is a ligand for CTLA-4 (T cell activation molecule). B7-2 shows minimal expression on unstimulated B cells, but is expressed at high density on activated B cells. It is distinct from B7-1 (previously referred to as B7). |
| Complete Growth Medium： | RPMI 1640 medium with 1% nonessential amino acids and 0.05 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Isotype： | IgG2a |
| Name of Depositor： | G Lazlo, KS Hathcock |
| Deposited As： | rat (B cell); mouse (myeloma) |
| References： | Hathcock KS, et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262: 905-907, 1993. PubMed: 7694361 Freeman GJ, et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7- deficient mice. Science 262: 907-909, 1993. PubMed: 7694362 Hancock WW, et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA 93: 13967-13972, 1996. PubMed: 8943044 Freeman GJ, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262: 909-911, 1993. PubMed: 7694363 |
